Gordon Foulkes

Foulkes has over 25 years of experience in biopharmaceutical executive management R&D and venture capital. He currently serves as the Executive Chairman and Chief Executive Officer of Thesan Pharmaceuticals. Most recently, Foulkes served as the founding CEO of Excaliard Pharmaceuticals from 2007-2009, and resumed that role in 2010, to lead the acquisition of Excaliard by Pfizer in 2011. He also served as a Managing Director of RiverVest Ventures from 2005-2010. Previously, Foulkes headed R&D, and served on the Boards of multiple biotechnology companies, including: Oncogene Science, Inc. (NASDAQ: OSIP; acquired by Astellas for $4 billion), Aurora Biosciences (NASDAQ: ABSC; acquired by Vertex for $590M), and Elitra Pharmaceuticals (acquired by Merck). He has had a lead role in securing more than 15 corporate partnerships, resulting in over $350 million in recognized revenues, as well as directly participated in raising over $165 million in private, IPO and follow-on public offerings. Prior to joining industry, Foulkes held academic positions at both MIT and the Medical Research Council (UK). He received his Ph.D. at the University of Dundee, Scotland.